Pharmacokinetic and pharmacodynamic trials for medication development in SUD. TO1 phase 1 cocaine drug interaction september 25, 2023 to march 24, 2025. N01DA-23-893
Ended Awarded Last action
- Contract number
- 75N95023F00001
- Awardee
-
Altasciences Clinical Kansas Inc. UEI WZ5RGEMMQ3W9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,838,615
Award facts
- Contract value 100% obligated
- $1,838,614.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Shawnee Mission, KS 66212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,838,615 |
About this award
The National Institute on Drug Abuse issued a $1,838,614.86 delivery order to Altasciences Clinical Kansas Inc. on September 25, 2023, for pharmacokinetic and pharmacodynamic trials supporting Phase 1 cocaine drug interaction studies in medication development for substance use disorders. The order runs through October 22, 2025.
Place of performance is Shawnee Mission, Kansas. The delivery order is priced on a firm fixed-price basis and was issued under a $21 million single-award indefinite delivery contract with NIDA (September 25, 2023, through September 24, 2028) that covers pharmacokinetic and pharmacodynamic trials for substance use disorder medication development, enabling NIDA to issue multiple task orders for advanced clinical research services.
Quick answers
Who was awarded contract 75N95023F00001?
75N95023F00001 was awarded to Altasciences Clinical Kansas Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 25, 2023.
How much is contract 75N95023F00001 worth?
The government has obligated $1,838,615 on 75N95023F00001.
Is contract 75N95023F00001 an order under another contract?
Yes. 75N95023F00001 is a delivery order under 75N95023D00019, an indefinite delivery contract.
Was contract 75N95023F00001 competed?
The extent of competition for 75N95023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award